Crossmark

Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC

Crossref DOI link: https://doi.org/10.1038/s41409-022-01846-9

Published Online: 2022-10-19

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chauvet, Paul https://orcid.org/0000-0001-6326-9283
Paviglianiti, Annalisa

Labopin, Myriam https://orcid.org/0000-0003-4514-4748
Labussière, Hélène

Boissel, Nicolas

Robin, Marie https://orcid.org/0000-0003-1388-9876
Maillard, Natacha

Ouachée-Chardin, Marie

Forcade, Edouard https://orcid.org/0000-0002-8873-2868
Poiré, Xavier https://orcid.org/0000-0003-1897-0227
Chantepie, Sylvain

Huynh, Anne

Bulabois, Claude Eric

Leclerc, Mathieu

Maury, Sébastien

Chevallier, Patrice

Cluzeau, Thomas https://orcid.org/0000-0002-6745-1127
Mear, Jean-Baptiste

Cornillon, Jérôme https://orcid.org/0000-0001-9830-8940
Bilger, Karin

Simand, Célestine

Beguin, Yves

Rubio, Marie-Thérèse

Yakoub-Agha, Ibrahim

Brissot, Eolia https://orcid.org/0000-0003-4471-418X
License Information

Text and Data Mining valid from 2022-10-19

Version of Record valid from 2022-10-19
More Information

Article History

Received: 13 June 2022

Revised: 3 October 2022

Accepted: 5 October 2022

First Online: 19 October 2022

Competing interests

: PChe has received honoraria from Amgen. The other authors declare no conflict of interest relative to this work.

Document is current

Any future updates will be listed below